Skip to main content

Vicore Pharma Holding AB

corporate_fare Company Profile

Vicore Pharma Holding AB

VCRE·NASDAQ·Life Sciences·CIK 0002124403

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company that develops therapies for respiratory diseases in Sweden. The company's primary product is Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG). Buloxibutid (C21) is currently in a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and in a Phase I clinical trial for treating pulmonary hypertension. Vicore Pharma also develops Almee, an investigational medical device that has completed Phase III clinical stage. Almee is designed to address the psychological impact of living with pulmonary fibrosis. The company has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor. Additionally, Vicore Pharma has a collaboration and development agreement with Alex Therapeutics AB to develop a digital app for interstitial lung diseases, including IPF. The company was founded in 2000 and is headquartered in Stockholm, Sweden.

Vicore Pharma Holding AB (NASDAQ:VCRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 4 items for VCRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 4 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for VCRE spans 6-K.

Recent high-impact activity:

  • Vicore Q3 Loss Widens to SEK 124.3M; Cash of SEK 772M Funds Runway Into H2 2028
  • Vicore's ASPIRE IPF Trial Clears Futility Analysis, Stays on Track for Mid-2027 Data
  • Vicore Pharma Posts Q2 Loss, Completes ASPIRE Enrollment, and Extends Cash Runway to 2028
  • Vicore Pharma Appoints Former GSK VP Rob Slack as Chief Scientific Officer

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 10,709 shares in VCRE as of the October 30, 2026 settlement, a 941.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 19.2% of VCRE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)10,709 shares as of October 30, 2026
Change vs prior period▲ 941.7%
Days to cover1.00 at avg daily volume of 22,655
Daily short volume (FINRA facilities)19.2% of 4,820 shares on November 20, 2026
5-day average short volume25.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

VCRE files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$10 +6.33% today
52-week range · as of 2026-11-05 $7.88 – $17.8
Market cap
$270.76M
Volume
13K (0.7× avg)
3-mo avg 19.8K
Live data · 2026-11-22 07:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VCRE - Latest Insights

VCRE
Nov 05, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.01
Real-time Price: $10.00 info
Change: -$0.0100 (-0.10%) info
Market Cap: $270.764M info
VCRE
Oct 22, 2026, 5:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.51
Real-time Price: $10.00 info
Change: -$0.510 (-5%) info
Market Cap: $270.764M info
VCRE
Aug 21, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.50
Real-time Price: $10.00 info
Change: -$2.50 (-20%) info
Market Cap: $270.764M info
VCRE
Jul 06, 2026, 9:16 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.53
Real-time Price: $10.00 info
Change: -$6.53 (-40%) info
Market Cap: $270.764M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets